Karyopharm Therapeutics (KPTI) Operating Expenses (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Operating Expenses came in at $51.9 million in Q4 2025, down 16.01% YoY from $61.8 million in Q4 2024, and down 12.39% on a QoQ basis from $59.3 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Operating Expenses (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Operating Expenses data on file, last reported at $51.9 million in Q4 2025.
- Quarterly Operating Expenses fell 16.01% year-over-year to $51.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $236.8 million (down 10.54% YoY) and the FY2025 annual result came in at $236.8 million, down 10.54% from the prior year.
- Operating Expenses retreated to $51.9 million in Q4 2025, from $59.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $82.6 million in Q2 2022 to a low of $933000.0 in Q1 2021.
- A 5-year average of $65.5 million and a median of $67.2 million in 2023 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 17993.18% in 2021, down 98.58% in 2021.
- Tracing KPTI's Operating Expenses over 5 years: stood at $79.3 million in 2021, then retreated by 14.95% to $67.4 million in 2022, then grew by 6.09% to $71.6 million in 2023, then declined by 13.6% to $61.8 million in 2024, then dropped by 16.01% to $51.9 million in 2025.
- The last three Operating Expenses figures came in at $51.9 million (Q4 2025), $59.3 million (Q3 2025), and $62.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 541.02 Mn |
| 10 | Karyopharm Therapeutics | 55.42 Mn | 55.42 Mn | 32.35 Mn | 55.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.96 Mn |
| Dec 31, 2025 | 51.92 Mn |
| Sep 30, 2025 | 59.26 Mn |
| Jun 30, 2025 | 62.32 Mn |
| Mar 31, 2025 | 63.27 Mn |
| Dec 31, 2024 | 61.82 Mn |
| Sep 30, 2024 | 65.07 Mn |
| Jun 30, 2024 | 70.91 Mn |
| Mar 31, 2024 | 66.89 Mn |
| Dec 31, 2023 | 71.56 Mn |
| Sep 30, 2023 | 67.27 Mn |
| Jun 30, 2023 | 67.15 Mn |
| Mar 31, 2023 | 69.60 Mn |
| Dec 31, 2022 | 67.45 Mn |
| Sep 30, 2022 | 66.98 Mn |
| Jun 30, 2022 | 82.59 Mn |
| Mar 31, 2022 | 82.26 Mn |
| Dec 31, 2021 | 79.31 Mn |
| Sep 30, 2021 | 81.50 Mn |
| Jun 30, 2021 | 71.65 Mn |